Immatics

Immatics Equity

The The Equity of Immatics (IMTX) as of Nov 19, 2026 is 484.10 M EUR. In the previous year, The Equity was 574.84 M EUR — a change of -15.79% (lower).

Equity

484.10 MEUR

YoY

-15.79%

Last updated:

In 2025, Immatics's equity was 484.10 M EUR, a -15.79% increase from the 574.84 M EUR equity in the previous year.

The Immatics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
-41.86 M EUR
Jan 1, 2020
104.26 M EUR
Jan 1, 2021
24.06 M EUR
Jan 1, 2022
213.16 M EUR
Jan 1, 2023
225.08 M EUR
Jan 1, 2024
574.84 M EUR
Jan 1, 2025
484.10 M EUR
The Immatics Equity history
YEAREquityYoY
484.10 MEUR-15.79%
574.84 MEUR+155.39%
225.08 MEUR+5.59%
213.16 MEUR+785.86%
24.06 MEUR-76.92%
104.26 MEUR-349.09%
-41.86 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immatics Stock analysis

What does Immatics do? Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors through Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). The company's pipeline includes eight therapeutic programs, with four in clinical trials: IMA201 (MAGEA4/8), IMA202 (MAGEA1), ACTolog IMA 101 (Multi-target pilot trial), and IMA203 (PRAME). Four programs are in preclinical development, such as IMA204 (COL6A3) and IMA401 (Cancer testis antigen). Immatics generates revenue through licensing agreements and potential future sales of its therapies, targeting pharmaceutical companies and research institutions seeking advanced cancer treatments. The company's clinical-stage therapies are designed to enable robust T-cell responses against cancer targets, with programs like IMA201 and IMA202 focused on solid tumors. IMA203 addresses both hematological and solid cancers, while preclinical programs like IMA401 and IMA402 target cancer testis antigens. Immatics partners with biopharmaceutical firms to advance its pipeline, leveraging its TCR technology platform to develop therapies for unmet medical needs in oncology. Immatics' revenue model relies on strategic partnerships and licensing deals with pharmaceutical companies, which fund clinical development and gain access to its proprietary TCR platform. The firm's focus on solid tumors and hematological cancers attracts interest from major biopharmaceutical players looking to expand their oncology portfolios. Through its eight therapeutic programs, Immatics aims to deliver innovative treatments that address high unmet medical needs in cancer therapy. Immatics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Immatics's Equity

Immatics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Immatics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Immatics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Immatics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Immatics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Immatics stock

The Equity of Immatics is 484.10 M EUR in 2025.

The Equity of Immatics changed from 574.84 M EUR to 484.10 M EUR, representing a -15.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Immatics since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Immatics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Immatics

All Key Metrics — Immatics